Cabaletta Bio reports strong rese-cel efficacy data in myositis, SLE, and scleroderma at EULAR 2025

Cabaletta Bio, Inc.

• 7 of 8 myositis patients achieved clinical response off all immunomodulators; all 4 ASyS/DM patients achieved meaningful TIS response.
• All 7 SLE patients achieved clinical response off immunomodulators and glucocorticoids; all non-renal SLE patients achieved DORIS.
• Both scleroderma patients showed meaningful mRSS improvements after discontinuing all immunomodulators and steroids, sustained to 6 months.
• In 18 patients with ≥4 weeks follow-up, 94% had no or Grade 1 CRS; 89% had no ICANS; enrollment accelerated to 51 patients actively enrolled.
• Company terminated ATM program with TD Cowen; prior sales of ~2.6M shares for $7.9M gross proceeds; $192M unused capacity cancelled.